Cargando…
The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
BACKGROUND: Treatment with immune checkpoint inhibitors (ICIs) targeting CTLA-4 and the PD-1/PD-L1 axis is effective against many cancer types. However, due in part to unresponsiveness or acquired resistance, not all patients experience a durable response to ICIs. HBI-8000 is a novel, orally bioavai...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404302/ https://www.ncbi.nlm.nih.gov/pubmed/34461854 http://dx.doi.org/10.1186/s12885-021-08702-x |